NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 127 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $55,770 | -18.7% | 13,669 | 0.0% | 0.01% | -20.0% |
| Q4 2022 | $68,618 | -61.7% | 13,669 | 0.0% | 0.02% | -64.3% |
| Q3 2022 | $179,000 | +2.3% | 13,669 | 0.0% | 0.04% | -10.6% |
| Q2 2022 | $175,000 | -15.9% | 13,669 | 0.0% | 0.05% | -9.6% |
| Q1 2022 | $208,000 | -14.0% | 13,669 | 0.0% | 0.05% | +10.6% |
| Q4 2021 | $242,000 | -15.7% | 13,669 | 0.0% | 0.05% | +4.4% |
| Q3 2021 | $287,000 | -20.1% | 13,669 | -25.0% | 0.04% | +2.3% |
| Q2 2021 | $359,000 | -32.3% | 18,225 | 0.0% | 0.04% | -55.1% |
| Q1 2021 | $530,000 | -4.0% | 18,225 | 0.0% | 0.10% | +75.0% |
| Q4 2020 | $552,000 | -4.8% | 18,225 | -50.0% | 0.06% | -65.4% |
| Q3 2020 | $580,000 | -39.5% | 36,451 | -25.0% | 0.16% | -47.6% |
| Q2 2020 | $959,000 | – | 48,602 | – | 0.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greenspring Associates, LLC | 1,573,357 | $47,665,000 | 61.89% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $114,111,000 | 60.06% |
| Column Group LLC | 15,396,116 | $466,502,000 | 42.31% |
| Ponoi II Management, LLC | 1,298,908 | $39,357,000 | 28.68% |
| Ponoi Management, LLC | 1,298,908 | $39,357,000 | 22.52% |
| Euclidean Capital LLC | 2,083,602 | $63,133,000 | 13.36% |
| Aquilo Capital Management, LLC | 1,005,534 | $30,463,000 | 6.33% |
| Octagon Capital Advisors LP | 75,227 | $2,279,000 | 0.79% |
| Jasper Ridge Partners, L.P. | 308,750 | $9,354,000 | 0.41% |
| Point72 Asset Management, L.P. | 1,761,157 | $53,354,000 | 0.26% |